Emerging strategies to disrupt the central TGF- β axis in kidney fibrosis

Chronic kidney disease (CKD) affects more than 20 million people in the US and the global burden of this disorder is increasing. Many affected individuals will progress to end stage kidney disease (ESKD) necessitating dialysis or transplantation. CKD is also a major independent contributor to the risk of cardiovascular morbidity and mortality. Tubulointerstitial fibrosis is a final common pathway for most causes of progressive CKD. Currently there are no clinically available therapies targeting fibrosis that can slow the decline in kidney function.
Source: Translational Research - Category: Research Authors: Tags: Review Article Source Type: research